drugset / Trial / NCT07616089
Phase I Study of FXS0683 in the Treatment of Blood Tumors
Phase 1
Not yet recruiting
228 enrolled
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
NaSingle-groupOpen-labelTreatment
Summary
This is a first-in-human, multicenter, open-label, single-arm Phase I study of FXS0683 in participants with relapsed or refractory hematologic malignancies to evaluate safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity, and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D).
Timeline
- Start
- 2026-06-01
- Primary completion
- 2028-08-07
- Completion
- 2029-08-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FXS0683 | Unknown | — | Oral |